Nova Vision logo

NovaVision™ Announces Launch of New Visual Assessment Device CentraVIEW™ at April’s AAN Meeting

04/03/2006

04/03/2006 » At the American Academy of Neurology's (AAN) annual meeting in April, NovaVision™ announced the new product launch of CentraVIEW™. CentraVIEW™ is an FDA-cleared visual assessment device that enables physicians and clinical staff at rehabilitation centers and group practices to provide visual function tests.

What it Does

CentraVIEW™ screens patients for central visual field deficits caused primarily by stroke or traumatic brain injury (TBI) by administering a 5-7 minute assessment test on an easy-to-use, compact medical device.

What it Shows

Results are available in a patient report immediately after the test is concluded. The report includes a visual field grid and information that provides the ability to determine if a central field deficit exists while uncovering specific performance trends. Undetected visual field defects may adversely impact other rehabilitation modalities.

Ongoing Client Support

Therapy for Diagnosed Patients

Patients who have been administered a CentraVIEW™ test and whose results indicate a potential central visual field deficit may be candidates for NovaVision™ VRT™ Vision Restoration Therapy™ (VRT™). NovaVision™ Partner Centers offer a comprehensive VRT™ diagnostic evaluation followed by customized vision therapy for these patients. VRT™ is a daily, at-home vision therapy performed on an FDA-cleared medical device that may restore some of the lost vision caused by a stroke or TBI.

Contact

If you are a patient or caregiver seeking more information on VRT, please visit our Patient Education Center.

Patient Education